Dr. Bergsland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero St
San Francisco, CA 94143Phone+1 415-353-9888Fax+1 415-353-7150
Education & Training
University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 1995
University of California (San Francisco)Residency, Internal Medicine, 1990 - 1992- University of California (San Francisco)Internship, Internal Medicine, 1989 - 1990
University of Minnesota Medical SchoolClass of 1989
Certifications & Licensure
CA State Medical License 1990 - 2026- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2005 Jun 08
- Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors Start of enrollment: 2006 Aug 01
- RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Start of enrollment: 2009 Jun 25
- Join now to see all
Publications & Presentations
PubMed
- 124 citationsIntratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.Lee B. Rivera, David Meyronet, Valérie Hervieu, Mitchell J. Frederick, Emily K. Bergsland
Cell Reports. 2015-04-28 - 67 citationsFirst-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela N. Munster, Rahul Aggarwal, David S. Hong, Jan H.M. Schellens, Ruud van der Noll
Clinical Cancer Research. 2016-04-15 - 197 citationsTelotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.Matthew H. Kulke, Dieter Hörsch, Martyn Caplin, Lowell Anthony, Emily K. Bergsland
Journal of Clinical Oncology. 2017-01-01
Lectures
- New Multidisciplinary Approaches to Diagnosis and Palliation in Hepato-Pancreato-Biliary TumorsASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(Alliance A021202).2019 ASCO Annual Meeting - 6/1/2019
- NANETS Neuroendocrine Tumor Symposium - "Emerging Targets & Therapeutic Advances in NET Management"North American Neuroendocrine Tumor Society(NANETS), Charleston, South Carolina - 10/4/2013
- Join now to see all
Press Mentions
The 2020 Gastrointestinal Cancers Symposium: What to ExpectJanuary 17th, 2020
The Bay Area's Top Doctors of 2019January 17th, 2019
OncLive® Hosts State of the Science Summit™: Gastrointestinal MalignanciesFebruary 22nd, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
